Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension.

Trial Profile

Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Candesartan cilexetil (Primary) ; Candesartan cilexetil/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 12 Jul 2010 Actual patient number (107) added as reported by ClinicalTrials.gov.
    • 12 Jul 2010 Actual end date added to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 12 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top